Israeli artificial intelligence startup CytoReason recently announced the completion of an $80 million funding round, with investors including industry giants such as Nvidia, Pfizer, OurCrowd, and Thermo Fisher Scientific. The company plans to use the funds to accelerate the development of its AI platform for disease modeling and drug discovery.Founded in 2016 and headquartered in Tel Aviv, CytoReason's AI platform extracts insights from human disease data to create computational disease models